Literature DB >> 23396645

Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapy().

B Corcioni1, L Santilli, S Quercia, C Zamagni, D Santini, M Taffurelli, S Mignani.   

Abstract

PURPOSE: To evaluate the response of breast cancers to neoadjuvant chemotherapy (NAC) with second-generation contrast-enhanced ultrasound (CEUS) and magnetic resonance (MR).
MATERIALS AND METHODS: We studied 16 women aged 33-74 years (mean, 53 years; median, 38 years) with locally advanced breast carcinoma or large operable breast cancer (>2 cm; T2-T4, N0-N3, M0) that had been detected by mammography, conventional ultrasonography, and biopsy. CEUS (with SonoVue, 5 ml) and MR (with Gd-DTPA; 0.2 mM/kg) were performed under blinded conditions before, during, and after 6-8 cycles of NAC. Lesions were measured and time/signal intensity (T/SI) curves were calculated during both the examinations. The data obtained were analyzed in light of the results of surgical pathology.
RESULTS: Six patients had complete responses manifested by the disappearance of enhancement at both CEUS and MR. Six others had partial responses (reduction of lesion enhancement >50%). In 5/6, T/SI curves obtained with CEUS and MR were both indicative of malignancy (flat curves at CEUS, type I curves at MR); the sixth had a discontinuous curve at CEUS and a type II curve at MR. Four patients had lesional enhancement reductions of <50%. In 3, concordant pictures emerged from the analysis of T/SI curves (discontinuous curves in CEUS, type II and III curves in MR); the fourth had a flat CEUS curve and a type I MR curve. Responses to NAC classified on the basis of MR and CEUS findings showed good correlation with the pathological response.
CONCLUSIONS: T/SI curves recorded during CEUS correlate with those obtained during MR and may be a valid index of response to the therapy.

Entities:  

Keywords:  Breast cancer; Breast ultrasonography; Contrast media; Contrast-enhanced US; MRI

Year:  2008        PMID: 23396645      PMCID: PMC3553156          DOI: 10.1016/j.jus.2008.09.007

Source DB:  PubMed          Journal:  J Ultrasound        ISSN: 1876-7931


  9 in total

1.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?

Authors:  C K Kuhl; P Mielcareck; S Klaschik; C Leutner; E Wardelmann; J Gieseke; H H Schild
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

Review 2.  Medical treatment of early breast cancer. IV: neoadjuvant treatment.

Authors:  Ian Smith; Susan Chua
Journal:  BMJ       Date:  2006-01-28

3.  Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients.

Authors:  Takashi Kanazawa; Sadako Akashi-Tanaka; Eriko Iwamoto; Miyuki Takasugi; Tadahiko Shien; Takayuki Kinoshita; Kunihisa Miyakawa; Chikako Shimizu; Masashi Ando; Noriyuki Katsumata; Yasuhiro Fujiwara; Takashi Fukutomi
Journal:  Breast J       Date:  2005 Sep-Oct       Impact factor: 2.431

Review 4.  Neoadjuvant chemotherapy in breast cancer.

Authors:  H Charfare; S Limongelli; A D Purushotham
Journal:  Br J Surg       Date:  2005-01       Impact factor: 6.939

5.  Benign and malignant breast lesions: efficacy of real time contrast-enhanced ultrasound vs. magnetic resonance imaging.

Authors:  P Ricci; V Cantisani; L Ballesio; E Pagliara; E Sallusti; F M Drudi; F Trippa; F Calascibetta; S M Erturk; M Modesti; R Passariello
Journal:  Ultraschall Med       Date:  2007-02       Impact factor: 6.548

6.  MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy.

Authors:  Fabienne Thibault; Claude Nos; Martine Meunier; Carl El Khoury; Liliane Ollivier; Brigitte Sigal-Zafrani; Krishna Clough
Journal:  AJR Am J Roentgenol       Date:  2004-10       Impact factor: 3.959

7.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

8.  Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy.

Authors:  A Rieber; H-J Brambs; A Gabelmann; V Heilmann; R Kreienberg; T Kühn
Journal:  Eur Radiol       Date:  2002-02-14       Impact factor: 5.315

9.  Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.

Authors:  J Herrada; R B Iyer; E N Atkinson; N Sneige; A U Buzdar; G N Hortobagyi
Journal:  Clin Cancer Res       Date:  1997-09       Impact factor: 12.531

  9 in total
  8 in total

1.  Impact of parametric imaging on contrast-enhanced ultrasound of breast cancer.

Authors:  Aya Noro; Takashi Nakamura; Toshiko Hirai; Masayo Haga; Toyoki Kobayashi; Akinobu Hayashi; Yuji Kozuka; Tokiko Nakai; Toru Ogura; Tomoko Ogawa
Journal:  J Med Ultrason (2001)       Date:  2016-01-22       Impact factor: 1.314

2.  Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Sandy C Lee; Edward Grant; Pulin Sheth; Agustin A Garcia; Bhushan Desai; Lingyun Ji; Susan Groshen; Darryl Hwang; Mary Yamashita; Linda Hovanessian-Larsen
Journal:  J Ultrasound Med       Date:  2017-02-02       Impact factor: 2.153

Review 3.  Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.

Authors:  Anna G Sorace; Sara Harvey; Anum Syed; Thomas E Yankeelov
Journal:  Semin Oncol Nurs       Date:  2017-09-15       Impact factor: 2.315

4.  Comparison of MRI and US in Tumor Size Evaluation of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Authors:  Onur Taydaş; Gamze Durhan; Meltem Gülsün Akpınar; Figen Başaran Demirkazık
Journal:  Eur J Breast Health       Date:  2019-04-01

5.  CEUS helps to rerate small breast tumors of BI-RADS category 3 and category 4.

Authors:  Jian-xing Zhang; Li-shan Cai; Ling Chen; Jiu-long Dai; Guang-hui Song
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

6.  Three-dimensional Contrast-enhanced Ultrasound in Response Assessment for Breast Cancer: A Comparison with Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathology.

Authors:  Wan-Ru Jia; Lei Tang; Deng-Bin Wang; Wei-Min Chai; Xiao-Chun Fei; Jian-Rong He; Man Chen; Wen-Ping Wang
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

7.  Is there a Role for Contrast-enhanced Ultrasound in the Detection and Biopsy of MRI Only Visible Breast Lesions?

Authors:  Aki Nykänen; Otso Arponen; Anna Sutela; Ritva Vanninen; Mazen Sudah
Journal:  Radiol Oncol       Date:  2017-11-29       Impact factor: 2.991

8.  Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer.

Authors:  Yunju Kim; Sung Hun Kim; Byung Joo Song; Bong Joo Kang; Kwang-Il Yim; Ahwon Lee; Yoonho Nam
Journal:  Korean J Radiol       Date:  2018-06-14       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.